For a long time, post-market was treated as a phase that comes after<\/em> the study. Today, that approach no longer works.<\/p> Medical devices, especially digital and connected ones, continue to generate data long after the last patient visit. The question is no longer: Today, PMS is no longer:<\/p> It has become a process that is:<\/p> This radically changes how clinical studies must be designed.<\/p> Because evidence is no longer something you \u201cclose\u201d at the end of the trial. Real-world data holds enormous value. Without defined criteria:<\/p> The difference is not made by the amount of data collected. An effective PMS does not start with more data. It requires:<\/p> This is where a CRO truly makes the difference: not by collecting more data, but by governing the data that already exists in a way that protects decisions.<\/p> Today, a reliable CRO does more than execute surveillance activities.<\/p> It helps structure PMS already during the study design phase, it ensures coherence between pre-market and post-market evidence, and protects both sponsor and device over time<\/p> Because real evidence does not end with the last patient. It begins when the device enters real life.<\/p> The value of a clinical study today is not measured only by its final results. When a clinical study changes its nature For a long time, post-market was treated as a phase that comes after the study.A necessary surveillance activity, but separate from clinical research itself. Today, that approach no longer works. Medical devices, especially digital and connected ones, continue to generate data long after the last patient visit.And that […]<\/p>\n","protected":false},"author":5,"featured_media":5023,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4],"tags":[8,52],"class_list":["post-4722","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","tag-clinical-trials","tag-real-world-data"],"yoast_head":"\n
A necessary surveillance activity, but separate from clinical research itself.<\/p>
And that is precisely where the real test of robustness begins.<\/p>
\u201cDid the study go well?\u201d<\/strong>
But:
\u201cAre we able to govern what happens after?\u201d<\/strong><\/p>Post-Market Surveillance is no longer a formality<\/h2>
It becomes something you must sustain over time.<\/p>The real challenge: real-world data<\/h2>
But without method, it can quickly become a problem instead of a resource, because signals are rarely clear-cut, populations are heterogeneous and usage contexts are highly variable<\/p>
It is made by the ability to interpret it clinically and strategically.<\/p>Governing the path from RWD to decision<\/h2>
It starts with better governance.<\/p>The role of a CRO in modern Post-Market<\/h2>
Evidence today is a lifecycle responsibility<\/h2>
It is measured by its ability to support the device over time, and that requires method and vision. If post-market is treated as a regulatory obligation, it becomes a risk.
If it is treated as part of the lifecycle, it becomes a guarantee.<\/p>","protected":false},"excerpt":{"rendered":"